Table 2. Cox proportional hazards model for breast cancer specific mortality.
|
Univariate analysis |
Multivariate analysis (n=247) |
|||
|---|---|---|---|---|
| Variable | RR (95% CI) | P-value | RR (95% CI) | P-value |
| Tumour size (cm) | ||||
| <2 | 1.0 | 1.0 | ||
| ⩾2 | 2.8 (1.6-4.9) | 0.0002 | 1.6 (0.9-3.0) | 0.1 |
| Nuclear gradea | 2.5 (1.7-3.5) | 0.0001 | 1.6 (1.03-2.4) | 0.04 |
| ER status | ||||
| Positive | 1.0 | 1.0 | ||
| Negative | 3.0 (1.8-4.8) | 0.0001 | 1.7 (0.95-3.0) | 0.07 |
| Lymph nodes | ||||
| Negative | 1.0 | 1.0 | ||
| Positive | 2.5 (1.5-4.4) | 0.0007 | 2.3 (1.3-3.4) | 0.004 |
| Mutation carrier status | ||||
| Non-carriers | 1.0 | 1.0 | ||
| BRCA1 carriers | 1.7 (0.9-3.4) | 0.1 | ||
| BRCA2 carriers | 1.9 (0.6-6.2) | 0.3 | ||
| BRCA1/BRCA2 carriers | 1.8 (0.96-3.2) | 0.07b | 1.1 (0.6-2.0) | 0.8b |
| p53 IHC | ||||
| Negative | 1.0 | 1.0 | ||
| Positive | 2.5 (1.5-4.1) | 0.0003 | 1.3 (0.7-2.2) | 0.4 |
| GMPa | 2.4 (1.6-3.5) | 0.0001 | 1.9 (1.2-3.0) | 0.006 |
ER=oestrogen receptor; GMP=glomeruloid microvascular proliferation; IHC=immunohistochemistry; MVD=microvascular density. The model was adjusted for cases with missing tumour size (n=13) and missing lymph node status (n=23).
a
As a continuous variable.
b
BRCA1/BRCA2 carriers combined compared with non-carriers.